|
Jun 28
|
IceCure Medical (NASDAQ:ICCM) shareholders have earned a 51% CAGR over the last five years
|
|
Jun 25
|
Sector Update: Health Care Stocks Softer Wednesday Afternoon
|
|
Jun 25
|
IceCure Medical's Board Approves $10 Million Rights Offering
|
|
Jun 25
|
IceCure Announces Record Date for Rights Offering for Up to $10 Million
|
|
May 6
|
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
|
|
Jan 3
|
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
|
|
Oct 7
|
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
|
|
Oct 3
|
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
|
|
Aug 28
|
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
|
|
Jun 24
|
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
|
|
Jun 12
|
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
|
|
May 28
|
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
|
|
May 21
|
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
|
|
May 20
|
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase
|
|
Mar 27
|
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
|
|
Jan 16
|
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
|
|
Jan 12
|
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
|
|
Jan 10
|
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
|
|
Nov 29
|
IceCure's ProSense® Deepens Regulatory Approval in India
|
|
Nov 28
|
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
|